Michael Platten, MD

Double ERC success for DKFZ researchers With its Proof of Concept (PoC) grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research results. Two scientists from the German C...

Double ERC success for DKFZ researchers: Hellmut Augustin @hellmutaugustin.bsky.social and Michael Platten @michael-platten.bsky.social have been selected by the European Research Council @erc.europa.eu for the prestigious Proof of Concept (PoC) grants. #ERCPoC 👏
t1p.de/zau31

Immunosuppressive mechanisms and therapeutic interventions shaping glioblastoma immunity - Nature Cancer In this Review, Golebiewska and colleagues summarize the main features of the immunosuppressive microenvironment in glioblastoma (GBM) and discuss how different therapeutic approaches reshape GBM immu...

Can immunotherapy ever work in #glioblastoma?

In a new #NatureCancer review, we share our perspective on current limitations and future directions:
www.nature.com/articles/s43...

#NORLUX, #LIH , @fnr.lu #TELEVIE, @glioresolve.bsky.social, @michael-platten.bsky.social

👉 We are excited to announce that the #EANO2025 Abstract Book is now available online! Download & explore it today: lnkd.in/dg79p6wM

#AbstractBook #NeuroOncology #neurosurgery #cancernurse #neuropathology #radiotherapy #AHP #btsm

This month’s cover illustration depicts distinct malignant glioma (upper left) and metastatic (bottom right) TMEs as collages of aperiodic penrose tiles overlaid on a stylized positron emission tomography (PET) scan of the brain.

The October issue of #ScienceImmunology is out!

This month's cover highlights a Review that delves into brain tumor development and examines factors contributing to the immunosuppressive brain tumor microenvironment. Learn about this and more: https://scim.ag/46HgHcl

The immunology of brain tumors The cellular and molecular determinants of the antigenicity of brain tumors and the immunosuppressive brain tumor microenvironment are reviewed.

The immunology of brain tumors | Science Immunology www.science.org/doi/10.1126/...

Happy to share this review article by @lukasbunse.bsky.social, Theresa Bunse and I @platten-lab.bsky.social, Michael Kilian, Fran Quintana @quintanalabhms.bsky.social.

🧠 Recently published in Neuro-Oncology: EANS–EANO Guidelines on the Extent of Resection in Gliomas. We’re proud to share the outcome of collaborative effort by the joint task force of EANS and EANO, providing evidence-based recommendations for clinical practice.
🔗 academic.oup.com/neuro-oncolo...

💡Only a few seats left for the EANO Tumor Board 2025, taking place on October 15 in Prague. Join us for interactive case-based discussions and expert insights. Registration is free for EANO members. Please register by October 3.
Learn more: www.eano.eu/eanomeetings...

Neuro-Oncology Pediatrics - explore the first issue

Discover Neuro-Oncology Pediatrics, a new #OA journal launched by @eanoassociation.bsky.social & @neuroonc.bsky.social with editorial leadership from EANO, SNO, & ASNO, focused on advancing care for children and young adults with CNS tumors.

See the first articles: oxford.ly/4mNN1iF

📣 New journal launch! Neuro-Oncology Pediatrics is live — an open-access journal advancing global research and care for children & young adults with brain tumors.
A joint EANO & @neuroonc.bsky.social initiative.
🔗 Read more: www.eano.eu/about/news/n...
#NeuroOncology @oxfordacademic.bsky.social

an incredibly dedicated team of clinical trialists, basic and translational researchers and immune monitoring team @dkfz.bsky.social, @dkfz-iic.bsky.social, I have the privilege to work with with the goal to develop a viable tratment for patients with this devastating disease. 5/5

@neurooncologyhd.bsky.social @neurooncotue.bsky.social, Frankfurt, Mannheim, all patients and their relatives, Roche for the in-kind contribution of atezolizumab, the fantastic research collaborators @bihatcharite.bsky.social and HI-TRON, and first and foremost 4/

in this "reverse translation" trial which was supported by the German Cancer Aid. Huge thanks to @dkfz.bsky.social as the trial sponsor, the fantastic NCT Trial Center, all participating sites from the Neurooncology Working Group @krebsgesellschaft.bsky.social 3/

A H3K27M-targeted vaccine in adults with diffuse midline glioma - Nature Medicine In this compassionate use study, treatment of adult patients with H3K27M-mutant diffuse midline glioma with a long peptide vaccine targeting H3K27M led to vaccine-induced peripheral T cell immune resp...

combined with radiotherapy and the immune checkpoint inhibitor atezolizumab. The trial was based on encouraging results in patients with recurrent diffuse midline gliomas

www.nature.com/articles/s41...

We will now follow-up our patiens, analyze the data and continue our analyses 2/

Excited to announce that we have completed accrual of the INTERCEPT-H3 trial (NCT04808245). This phase 1 first-in-human trial explores safety and immunogenicity of a long peptide vaccine targeting the clonal driver mutation H3K27M in adult patients with newly diagnosed diffuse midline gliomas 1/

📣 Have you heard? Registration for #EANO2025, taking place Oct 16-19, 2025 in #Prague (CZ) is open! Don’t miss out on this fantastic experience to meet experts in the field of #NeuroOncology. Early Bird fees available until July 31, 2025. 👉 eano.eu/eano2025/reg... #braincancer #medsky

🧠 June 8 is #WorldBrainTumorDay — raising awareness & understanding of brain tumors.
EANO supports progress in #NeuroOncology through research, education & collaboration.
🔗 Learn more: www.eano.eu
#btsm #BrainTumor #Oncology

Der Wissenschaftsrats-Vorsitzende Wolfgang Wick mit dem nebenstehenden Zitat "Wir brauchen eigenständige Wissenschaftsinfrastrukturen in Europa", das aus einem FAZ-Gastbeitrag vom 4.6.25 stammt.

Wissenschaft braucht verlässliche Infrastrukturen - viele davon liegen noch in den USA. Der WR-Vorsitzende
@wickwolfgang.bsky.social fordert in der @faznet.bsky.social eine europäische Strategie für mehr Unabhängigkeit👉 www.faz.net/aktuell/wiss...
#DigitaleSouveränität #Forschung #Infrastruktur

Join us this week on Thursday (22nd May) for our next i2 seminar! This week it’s all about T cells in cancer!

The organizing committee of the UNITE conference would like to thank all speakers for their excellent presentations and all participants for the valuable discussions. @wickwolfgang.bsky.social @michael-platten.bsky.social

🧠 Join the next #EANOYoungsters Journal Club on June 5, 16:30–17:30 CEST!
Discussing: "Rapid molecular profiling of CNS tumors" www.nature.com/articles/s41... (Patel et al., Nat Med 2025)
📍Free & open to all EANO members
🔗 www.eano.eu
#NeuroOncology #BrainTumors #JournalClub

The second day of the UNITE conference. Today there will also be a contribution from a patient on the book “Alles gut? Alles gut.” by Marlene Assmann. www.jacobystuart.de/buecher-von-...

Bottom-up synthetic immunology - Nature Nanotechnology This Perspective highlights bottom-up molecular engineering and modular nanobiotechnological approaches for developing effective immunotherapeutics and their potential in personalized medicine.

The SynthImmune project by Heidelberg University& partner institutes advances a "bottom-up" synthetic biology approach to immunotherapies.
Hoping they do well in the German government's Excellence Strategy—anticipating the announcement on 22 May.

Perspective article: www.nature.com/articles/s41...

⏱️ Clock is ticking! Final call for abstract submissions for #EANO2025 in #Prague. Don't miss this chance to share your work contribute to the advancement of #NeuroOncology. Submit now via our official event website: www.eano.eu/eano2025/ until May 6, 2025, 23.59 CEST!
@oncoalert.bsky.social

Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy - Nature Biotechnology Tumor-reactive T cell receptors are rapidly identified from lymphocyte scRNA-seq data.

Fantastic initiative - we could offer to provide our predicTCR and makeTCR tools to identify tumor-reactive TCRs and clone them for testing.

www.nature.com/articles/s41...

www.biorxiv.org/content/10.1...

Wir freuen uns, die UNITE-Glioblastom-Konferenz ankündigen zu können, die am 14. und 15. Mai 2025 im DKFZ-Kommunikationszentrum in Heidelberg stattfinden wird. melden Sie sich heute an: www.unite-glioblastoma.de/unite-confer...

🚀 We are proud to launch the new "Ambassadors for the ERC" initiative, together with @ercgrantees.bsky.social !

We aim to empower researchers across Europe to advocate for frontier research. Find out more 👉 bit.ly/44bQzp7

🌟 Excited to see what can be achieved!

#Amb4ERC

Photo: Jung/DKFZ

@michael-platten.bsky.social has been selected and nominated as Ambassador for the ERC network. The @erc.europa.eu & the @ercgrantees.bsky.social launched the new Ambassadors on 28 April. This joint initiative aims to promote investment in frontier research and highlight the importance of #research.

🗓️ Only one week to go! The abstract submission deadline for #EANO2025 in #Prague is approaching fast. This is your opportunity to share your findings, collaborate with peers, and be recognized in the field of #NeuroOncology. Submit your abstract now: www.eano.eu/eano2025/ #btsm

Apply to DKFZ Marie Skłodowska Curie MasterClasses

Do you want to do your #postdoc in #cancerresearch with the most prestigious #fellowship in Europe? Apply to DKFZ Marie Skłodowska Curie MasterClasses by May 19. Projects in #cellandmolecularbiology #genomics #bioinformatics #immunology #medicaltechnology, #epidemiology.
Apply here: t1p.de/nx6tu

#brain #tumors | Michael Platten This is the research team DKFZ Deutsches Krebsforschungszentrum Helmholtz-Gemeinschaft Universität Heidelberg Universitätsmedizin Mannheim Neurooncology Heidelberg Health + Life Science Alliance I hav...

www.linkedin.com/posts/michae...